Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.46 |
| ▸ | MMP9 | P14780 | 8/20 | 0.46 |
| ▸ | MMP1 | P03956 | 8/20 | 0.46 |
| ▸ | MMP3 | P08254 | 7/20 | 0.46 |
| ▸ | MMP8 | P22894 | 5/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 3/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MMP7 | P09237 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6305546 | 1.00 | MMP2 (0.46) | MMP2MMP9MMP1MMP3MMP8 | |
| SCHEMBL6299582 | 0.88 | CRHBP (0.49) | MMP2MMP9MMP1MMP3MMP8 | |
| SCHEMBL6299579 | 0.88 | CRHBP (0.49) | MMP2MMP9MMP1MMP3MMP8 | |
| SCHEMBL7739612 | 0.87 | LTA4H (0.43) | MMP2MMP9HSP90AA1KMT2AMEN1 | |
| SCHEMBL7739608 | 0.87 | LTA4H (0.43) | MMP2MMP9HSP90AA1KMT2AMEN1 | |
| SCHEMBL6305496 | 0.78 | HDAC3 (0.35) | HDAC3 | |
| SCHEMBL6305494 | 0.78 | HDAC3 (0.35) | HDAC3 | |
| SCHEMBL7740143 | 0.77 | HSD17B2 (0.46) | MMP2MMP9MMP1MMP8KMT2A | |
| SCHEMBL7740669 | 0.77 | MMP2 (0.40) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL7740614 | 0.75 | CRHBP (0.50) | MMP1KMT2AMEN1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002480-A1 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | TAKAHASHI KANJI (JP) | 2004-01-01 | — | — | US | claimed |
| US-6569899-B1 | Such as 5-ethoxymethoxy-4(S)-(N-(4-iodophenylcarbonyl)amino) pentanoic acid methyl ester for inhibiting matrix metalloproteinase; for treatment of rheumatoid diseases, arthrosteitis, osteoarthritis, and osteoporosis | ONO PHARMACEUTICALS CO., LTD. (JP) | 2003-05-27 | — | — | US | claimed |
| EP-1167346-A1 | 4-AMINOBUTANOIC ACID DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-01-02 | — | — | EP | claimed |
| US-6924307-B2 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20040002480-A1 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | TAKAHASHI KANJI (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6569899-B1 | Such as 5-ethoxymethoxy-4(S)-(N-(4-iodophenylcarbonyl)amino) pentanoic acid methyl ester for inhibiting matrix metalloproteinase; for treatment of rheumatoid diseases, arthrosteitis, osteoarthritis, and osteoporosis | ONO PHARMACEUTICALS CO., LTD. (JP) | 2003-05-27 | — | — | US | disclosed |
| EP-1167346-A1 | 4-AMINOBUTANOIC ACID DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002480-A1 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | GABBR1, GABRB1, GABBR2 | MMP2 114/4885MMP9 39/4885MMP1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.